enGene logo
enGene
ENGN | NASDAQ
Chart Builder DCF Calculator
$1.89
-$0.52 (-21.58%)
At close: Nov 16, 2026, 4:00 PM ET
$1.94
+$0.05 (+2.65%)
After-hours: Nov 16, 2026, 7:47 PM ET

enGene Company Profile

Company profile explained

Company Profile

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Key Executives

Name Position
Ronald H. W. Cooper President, Chief Executive Officer & Director
Joan Connolly Chief Technology Officer
Amy Pott Chief Global Commercialization Officer
Anthony T. Cheung Consultant
Jill Buck Chief Development Officer
Kathleen Richton Senior VP of Finance, Principal Accounting & Financial Officer and Controller
Matthew Boyd Chief Regulatory Officer
Tara Place Senior Vice President of Human Resources
William J. Grossman Interim Chief Medical Officer & Director
enGene
enGene logo
Country Canada
IPO Date Feb 1, 2022
Industry Biotechnology
Sector Healthcare
Employees 82
CEO Ronald H. W. Cooper

Contact Details

4868 Rue Levy Montreal, QC H4R 2P1 Canada

Stock Details

Ticker Symbol ENGN
Exchange NASDAQ
Fiscal Year November - October
Reporting Currency USD
CIK Code 0001980845
CUSIP Number 29286X101
ISIN Number CA29286X1015
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.